Loading...
XNAS
MNKD
Market cap1.74bUSD
Dec 05, Last price  
5.68USD
1D
-0.53%
1Q
2.53%
Jan 2017
78.45%
IPO
-59.46%
Name

MannKind Corp

Chart & Performance

D1W1MN
XNAS:MNKD chart
P/E
63.21
P/S
6.11
EPS
0.09
Div Yield, %
—
Shrs. gr., 5y
7.73%
Rev. gr., 5y
35.27%
Revenues
286m
+43.50%
0100,00010,00020,000093,00050,00035,000000174,758,00011,745,00027,859,00063,038,00065,144,00075,442,00099,770,000198,962,000285,504,000
Net income
28m
P
-114,338,000-230,548,000-293,190,000-303,039,000-220,104,000-170,560,000-160,804,000-169,366,000-191,490,000-198,382,000-368,445,000125,664,000-117,333,000-86,975,000-59,729,000-57,240,000-91,791,000-112,169,000-11,938,00027,588,000
CFO
43m
+24.69%
-101,229,000-189,794,000-245,146,000-271,288,000-184,083,000-148,654,000-123,837,000-119,860,000-128,732,0004,086,000-57,232,000-78,090,000-64,778,000-37,731,000-88,483,000-28,128,000-61,709,000-80,679,00034,094,00042,511,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
URL
https://mannkindcorp.com/
IPO date
Jul 28, 2004
Employees
391
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT